 Home > Active Ingredient News > Drugs Articles > Courier raised more than US$250 million within one year of its establishment, and Xinwei is committed to developing targeted radioactive anticancer drugs

Courier raised more than US$250 million within one year of its establishment, and Xinwei is committed to developing targeted radioactive anticancer drugs

 Last Update: 2021-06-30
 Source: Internet
 Author: User

Tags

adenocarcinoma prostate treatment

lead

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 15, 2021, RayzeBio announced the completion of a Series C financing of US$108 million to further advance its pipeline of targeted radiopharmaceuticals for cancer treatment
.

By coupling radioisotopes with drugs that specifically bind to tumor surface proteins, targeted radiotherapy that delivers radioactive compounds into tumors is attracting high attention
.

Previously at the ASCO annual meeting, Novartis' 177Lu-PSMA-617 therapy reduced the risk of death in prostate cancer patients by 38% in a phase 3 clinical trial

RayzeBio focuses on the development of powerful radioactive targeted therapies for solid tumor targets that have been clinically validated
.

The macrocycle peptide-mimetics developed by the company has similar affinity and specificity as antibodies, and can specifically bind to the target on the tumor; at the same time, it has similar characteristics as small molecule drugs and can penetrate the tumor deeply.
And rapid and effective synthesis, is an effective carrier for targeted delivery of radiopharmaceuticals

The isotope actinium-225 used by the company is an isotope that releases alpha particles
.

The distance for alpha particles to act in tissues is very short, only a few cells wide

"Targeted radiopharmaceuticals represent a highly clinically validated treatment model
.

" said Dr.
Ken Song, RayzeBio's president and CEO.

The lead investor in C round of financing by the Venrock Healthcare Capital Partners, new investors, including Perceptive Advisors, capital Vivo (Vivo Capital), Acuta Capital Partners , Deerfield Management and the X-TCG
.

Also participating in the investment are existing investors in RayzeBio

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Hydrolysis amino acid fertilizer amino acid powder organic fertilizer 80% light yellow powder AA80 shihong

CAS No.: 65072-01-7

Agricultural Grade

$2500-2600/MT FOB

Triclosan China Manufacturer CAS 3380-34-5 Triclosan powder

CAS No.: 3380-34-5

Pharmacy Grade

$80-90/KG FOB

Benzenesulfonic acid,tetrapropylene-,calcium salt

CAS No.: 11117-11-6

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.